Thrombolysis therapy uses thrombolytic drugs that dissolve blood clots. Treatment of established arterial thrombosis includes the use of antiplatelet drugs and thrombolytic therapy. Treatment is by catheter-directed thrombolytic therapy, a type of thrombolysis. Thrombolytic therapy to abort a myocardial infarction is not always effective. Streptokinase (SK) is a thrombolytic medication and enzyme. Anticoagulants and thrombolytic medications also increase the likelihood of bleeding. Streptokinase, an enzyme produced by streptococcal bacteria, is one of the oldest thrombolytic drugs. In the past, streptokinase was the main thrombolytic chemical. Hemorrhagic stroke is a rare but serious complication of thrombolytic therapy. However, the efficacy of thrombolytic treatment is limited by hemorrhagic complications. After 12 hours, the risk of intracranial bleeding associated with thrombolytic therapy outweighs any benefit. Intracranial bleeding (ICB) and subsequent stroke is a serious side effect of thrombolytic use. The use of thrombolytic agents is contraindicated in this patient subset, however. Only patients with disabling symptoms are considered eligible for thrombolytic treatment. Thrombolytic therapy has become the treatment of choice.